Fresenius SE & Co KGaA (FREG.DE)
* CEO says still sees opportunities for Kabi to grow, both organically and via M&A
A federal judge has barred generic drug maker Fera Pharmaceuticals LLC from selling a generic version of Fresenius Kabi's injectable thyroid hormone levothyroxine, finding that Fresenius was likely to win a patent lawsuit against Fera.
(The following statement was released by the rating agency) LONDON, September 06 (Fitch) Fitch Ratings says German healthcare group Fresenius SE & Co KGaA's (FSE; BBB-/Stable, including Fresenius Medical Care AG & Co. KGaA (FMC), together Fresenius) acquisition of Spain-based private hospital group Quironsalud for an estimated EUR5.76bn, will have no impact on its existing ratings. Despite being predominantly debt-funded, the transaction will use headroom available under the current rating,
UPDATE 2-Germany's Fresenius takes expansion plans to new heights with $6.4 bln Spanish healthcare acquisition
* Price includes assumed debt, buys from CVC, senior managers
LONDON, Sept 6 European shares rose slightly on Tuesday and held near their highest levels since April supported on the day by the energy sector and a jump in shares of healthcare firm Fresenius which rose following an acquisition in Spain.
FRANKFURT, Sept 5 German healthcare group Fresenius agreed to take over Spain's biggest private hospital chain, Quironsalud, for 5.76 billion euros ($6.42 billion), cementing its position as Europe's largest private-sector hospital operator.
ZURICH Swiss specialty chemicals and pharmaceutical ingredients company Lonza has announced a deal worth up to $300 million to buy InterHealth Nutraceuticals, a developer and manufacturer of nutritional ingredients used in dietary supplements.
FRANKFURT The new boss of Fresenius, who in his previous job as head of finance worked on several takeover deals for the diversified German healthcare group, said large transactions might well remain his hallmark.
FRANKFURT, Aug 2 The new boss of Fresenius , who in his previous job as head of finance worked on several takeover deals for the diversified German healthcare group, said large transactions might well remain his hallmark.
(The following statement was released by the rating agency) FRANKFURT/BARCELONA/LONDON, July 29 (Fitch) Fitch Ratings has upgraded Fresenius Medical Care AG & Co. KGaA's (FMC) and Fresenius SE & Co. KGaA's (FSE; together Fresenius) Long-Term Issuer Default Ratings to 'BBB-' from 'BB+'. The Outlooks are Stable. Fitch has also upgraded the Short-Term IDR to 'F3' from 'B'. A full list of rating actions is below. The upgrade reflects Fresenius' improving business risk profile, driven by its inc